Electrical Pulses / Casp2 Cancer Research Results

EP, Electrical Pulses: Click to Expand ⟱
Features:

Electrical Pulses (Pulsed Electric Field therapies; PEF) are a bioelectromagnetic modality in oncology that delivers brief, high-voltage (or high-field) pulses to tissue to permeabilize membranes and/or ablate tumors. Clinically relevant categories commonly discussed:
(1) Reversible electroporation for drug/ion delivery (Electrochemotherapy, ECT; Calcium electroporation),
(2) Irreversible electroporation ablation (IRE; e.g., NanoKnife-type approaches), and
(3) Nanosecond PEF (nsPEF) aimed at intracellular targets.
Primary mechanisms (ranked):
1) Membrane electroporation → rapid loss of ionic homeostasis / enhanced transport (ECT) or irreversible disruption (IRE).
2) Ca2+ dysregulation (influx + organelle Ca2+ stress) → mitochondrial depolarization, ER stress, apoptosis/necrosis spectrum (pulse-width dependent).
3) Stress biology (ROS↑, inflammatory/DAMP signaling) → immunogenic cell death signals and microenvironment remodeling (often secondary/adaptive).
PK/Bioavailability relevance: systemic PK is mainly relevant only for ECT (bleomycin/cisplatin timing, tissue exposure); field-based effects themselves are local and device/geometry-limited rather than concentration-limited.
In-vitro vs systemic exposure: not concentration-driven (electric field–driven); however, many in-vitro protocols use idealized field homogeneity not achievable in heterogeneous tumors without image-guided electrode placement.
Clinical evidence: ECT and IRE have substantial human use (ECT for cutaneous/superficial tumors; IRE for selected solid tumors near critical structures). nsPEF remains mostly preclinical/early human and is still device- and protocol-evolving.


-Shorter, bipolar/high-frequency µs waveforms (H-FIRE) are repeatedly shown to reduce or eliminate muscle contractions versus classic monopolar IRE, improving tolerability and potentially reducing need for paralytics.
-Nanosecond pulses with fast rise times can overcome membrane charging delays and directly polarize organelles, which is why rise-time engineering becomes a first-order variable for intracellular effects (mitochondria/ER, Ca²⁺, ROS, regulated death programs).
-nsPEF / Nano-Pulse Stimulation (NPS) used as irreversible tumor ablation (intracellular emphasis). With ns pulses, fast rise times and short widths can drive intracellular membrane perturbation (not just plasma membrane), shifting biological response vs classic IRE. 
In nsPEF systems the main engineering challenge is not current or power, but:
  -generating fast rise times
  -maintaining transmission line impedance
  -preventing pulse distortion at the electrodes
Other important aspects of nsPEF
  -mainly an electric field effect: 
     -Membrane breakdown typically occurs around 0.5–1 V across the membrane,
      which corresponds to ~10–50 kV/cm fields in tissue.
  -ns pulses terminate before plasma channels develop.
  -impedance mismatch and cable dispersion is important
  -nsPEF often induces programmed cell death rather than thermal ablation
The hallmark of nsPEF is simultaneous targeting of multiple intracellular pathways, particularly:
  -Calcium signaling (Ca²⁺ release)
  -Mitochondrial apoptosis (ΔΨm↓, Caspase-9↑, Caspase-3↑)
  -ROS stress pathways
Research might show cancer cells have some greater sensitivity to nsPEF, 
but nsPEF affects both normal and cancer cells

Electrical Pulses / PEF Oncology Modality — Ranked Mechanistic Axes

Rank Pathway / Axis Cancer Cells (↑ / ↓ / ↔) Normal Cells (↑ / ↓ / ↔) TSF Primary Effect Notes / Interpretation
1 Membrane electroporation (Reversible vs Irreversible) ↑ permeabilization / disruption ↑ permeabilization / disruption P Immediate loss of membrane barrier Category mapping: Reversible EP → ECT / Ca-EP; Irreversible EP → IRE. Selectivity is largely geometric (field distribution) and cellular (repair capacity), not “cancer-only”.
2 ECT drug uptake (bleomycin/cisplatin) / intracellular access ↑ intracellular drug delivery ↑ intracellular drug delivery P→R Local chemosensitization Category: ECT is a delivery amplifier; efficacy depends on timing + local perfusion. Often enables potent effect from otherwise poorly permeant agents.
3 Ca2+ axis (influx, overload, ER–mitochondria coupling) ↑ Ca2+ dysregulation ↑ Ca2+ dysregulation P→R Mitochondrial stress, apoptosis/necrosis spectrum Pulse width and repetition strongly shape outcome; Ca electroporation leverages Ca2+-driven bioenergetic collapse as a drug-free approach.
4 Mitochondria / MPTP + bioenergetic collapse ↑ depolarization / ATP loss ↑ depolarization / ATP loss R Cell death execution + metabolic failure Often downstream of Ca2+ overload + membrane failure; nsPEF is frequently framed as more “intracellular/organellar” stress-forward than classic µs EP.
5 ROS (oxidative burst → signaling) ↑ (context-dependent) ↑ (context-dependent) R→G Stress signaling, damage amplification ROS can be secondary to Ca2+/mitochondria and/or electrochemical effects at electrodes. Direction and magnitude depend on pulse protocol, conductivity, and oxygenation.
6 NRF2 antioxidant response / adaptation ↑ (context-dependent; resistance role) ↑ (protective role) G Redox adaptation NRF2 upshifts can protect normal tissue but may also support tumor survival post-sublethal EP (repair/tolerance). Relevance rises when aiming for non-ablative or fractionated protocols.
7 Vascular axis (perfusion, endothelial effects) ↓ perfusion (often) / local ischemia ↓ perfusion (local) R Secondary tumor control via antivascular effects Prominent in ECT literature (composite antivascular + cytotoxic). In IRE, ECM sparing may preserve larger structures while still affecting microvasculature.
8 Immunogenic cell death / DAMP release ↑ immune priming signals ↔ (tissue-dependent) G Local-to-systemic immune modulation (adjunct potential) Most compelling as an adjunct (combo with checkpoint blockade, RT, etc.). Strength varies with ablation completeness, antigen burden, and microenvironment.
9 Clinical Translation Constraint ↔ ↔ — Deliverability / safety / field heterogeneity Constraints are dominated by geometry (electrode placement, tumor shape, conductivity), safety (muscle contractions, arrhythmia risk near heart, anesthesia needs), and protocol standardization; nsPEF still has broader device/protocol variability than ECT/IRE.


Casp2, caspase-2: Click to Expand ⟱
Source:
Type:
Caspase‑2 is an initiator caspase that, unlike other apoptotic caspases, can also function in non‐apoptotic pathways including DNA damage responses.
Its unique position in guarding genomic integrity has led to studies examining its tumor-suppressive potential.

Caspase‑2 plays complex roles in cancer biology. Generally, decreased expression or altered isoform distribution of caspase‑2 has been associated with impaired apoptotic responses, genomic instability, and poorer prognosis in several cancer types.
Scientific Papers found: Click to Expand⟱
6236- CUSP9,  EP,    Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro
- in-vitro, GBM, U251
Apoptosis↑, MOMP↓, Casp2↑, Bcl-2↓, Mcl-1↓, eff↑, OCR↓, OXPHOS↓, TumCMig↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

OXPHOS↓, 1,  

Mitochondria & Bioenergetics ⓘ

OCR↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Bcl-2↓, 1,   Casp2↑, 1,   Mcl-1↓, 1,   MOMP↓, 1,  

Migration ⓘ

TumCMig↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp2, caspase-2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:248  Target#:1063  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page